Improvements in outcomes with current chemotherapy and surgery treatment approaches for patients with osteosarcoma have plateaued over the past three decades necessitating new treatment paradigms. A novel therapy for osteosarcoma of MR-guided cryotherapy in conjunction with intratumoral injection of an immune adjuvant in the clinically relevant animal model of spontaneously occurring osteosarcoma in client-owned dogs with the intent of priming an adaptive immune response capable of delaying or preventing the occurrence of metastatic disease is demonstrated.
This abstract and the presentation materials are available to members only; a login is required.